The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment.
 
Vylyny Chat
No Relationships to Disclose
 
Robert Ferguson
No Relationships to Disclose
 
Danny Simpson
No Relationships to Disclose
 
Esther Kazlow
No Relationships to Disclose
 
Rebecca Lax
No Relationships to Disclose
 
Una Moran
No Relationships to Disclose
 
Melissa Wilson
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb
 
Anna C. Pavlick
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst); Millennium (Inst)
 
Ryan J. Sullivan
Honoraria - Roche/Genentech
Consulting or Advisory Role - ACI Clinical; Amgen; Array BioPharma; Biodesix; BiolineRx; Merck; Novartis; Takeda; WorldCare Clinical, LLC
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); BioMed Valley Discoveries (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Other Relationship - Boehringer Ingelheim
 
Keith Flaherty
Stock and Other Ownership Interests - Clovis Oncology; Loxo; Strata Oncology; X4 Pharma
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Asana Biosciences; Bristol-Myers Squibb; Genentech; Incyte; Lilly; Loxo; Merck; Novartis; Oncoceutics; Roche; Sanofi; Shattuck Labs; Tolero Pharmaceuticals
Research Funding - Novartis; Sanofi
 
Iman Osman
No Relationships to Disclose
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; Celldex; CytomX Therapeutics
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche; Sellas Life Sciences; WindMIL
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche; Sellas Life Sciences; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Novartis; Pieris Pharmaceuticals; Roche
 
Tomas Kirchhoff
No Relationships to Disclose